Eletriptan
- Generic Name
- Eletriptan
- Brand Names
- Relpax
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26N2O2S
- CAS Number
- 143322-58-1
- Unique Ingredient Identifier
- 22QOO9B8KI
Overview
Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.
Background
Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.
Indication
For the acute treatment of migraine with or without aura in adults.
Associated Conditions
- Migraine With Aura
- Migraine Without Aura
Clinical Trials
FDA Approved Products
Relpax
Manufacturer:STAT Rx USA LLC
Route:ORAL
Strength:40 mg in 1 1
Approved: 2012/08/13
NDC:16590-201
Eletriptan HBR
Manufacturer:Direct_Rx
Route:ORAL
Strength:40 mg in 1 1
Approved: 2023/10/11
NDC:72189-517
Relpax
Manufacturer:Rebel Distributors Corp
Route:ORAL
Strength:40 mg in 1 1
Approved: 2010/01/19
NDC:21695-871
Eletriptan Hydrobromide
Manufacturer:Aurobindo Pharma Limited
Route:ORAL
Strength:40 mg in 1 1
Approved: 2021/04/29
NDC:59651-105
Eletriptan Hydrobromide
Manufacturer:Aurobindo Pharma Limited
Route:ORAL
Strength:20 mg in 1 1
Approved: 2021/04/29
NDC:59651-104
Singapore Approved Products
RELPAX TABLET 40 mg
Manufacturer:Pfizer Italia S.r.l.
Form:TABLET, FILM COATED
Strength:40 mg
Online:Yes
Approved: 2002/01/14
Approval:SIN11767P
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath